Featured Research

from universities, journals, and other organizations

Progress in fight against tuberculosis

Date:
June 30, 2014
Source:
Lindau Meeting of Nobel Laureates
Summary:
Leading immunologists express confidence that clear advances in the fight against tuberculosis are within reach. "The old BCG vaccine against tuberculosis primarily activates only helper cells. The trick with our new vaccine is to additionally activate the killer cells, which enables us to trigger an improved immune system response," one expert says. In addition to research into vaccines, innovative treatments are also being investigated which attempt to entice the bacteria out of their macrophage hiding places.

Leading immunologists expect to see some clear advances in the fight against tuberculosis, an infectious disease that is widespread the world over. Professor Stefan Kaufmann, Director at the Max Planck Institute for Infection Biology in Berlin, echoed these sentiments at today's launch of the scientific programme for the 64th Lindau Nobel Laureate Meeting at Lindau, Germany. "In the past ten years, numerous attempts have been made to develop an improved vaccine. We are now justified in hoping that our vaccine will be effective," explained Professor Kaufmann. The vaccine developed by Kaufmann's research group is already undergoing Phase IIa clinical trials, during which its effectiveness and tolerability will be tested by trial participants. One-third of the world's population is infected with the tuberculosis pathogen Mycobacterium tuberculosis, and the disease claims 1.3 million lives each year.

Kaufmann attributes advances such as this in the fight against infectious diseases to the greater depth of knowledge acquired in recent decades about the body's own immune system defences. No fewer than three Nobel laureates who have played a major part in these discoveries are currently participating in the Lindau Nobel Laureate Meeting, which opened on Sunday. Jules Hoffmann from France, Bruce Beutler of the USA and Rolf Zinkernagel of Switzerland will be delivering presentations on the challenges facing modern immunology, one of the main emphases of the week-long programme. Between now and Friday, a total of 37 Nobel laureates will be engaged in an exchange of ideas with aspiring young scientists: over 600 selected undergraduates, doctoral students and post-docs from 80 countries, with the focus on physiology and medicine.

Stefan Kaufmann, Founding Director of the Max Planck Institute for Infection Biology and Professor of Microbiology and Immunology at the Charitι in Berlin, is one of the two scientific chairpersons of the meeting and played a major role in defining the programme. He has a clear perspective on the direction in which his research area will continue to develop: "Over the next few years we must come to understand the immune system in the context of systems biology." One of the keys to this understanding lies in identifying the molecular and functional diversity of immunocompetent cells. Another lies in investigating the complex interactions with the body's own, as well as foreign cells and substances. This knowledge will provide us with new approaches to the prevention and treatment of infectious diseases such as tuberculosis, and help to improve our understanding of allergies, autoimmune diseases and the body's own cancer surveillance mechanism.

The complexity of the biological and biochemical foundations that underlie the human immune system is one reason why tuberculosis, which has existed for thousands of years, is still being combated with a vaccine that is itself almost a hundred years old, and has proven to be of little effect; and why a six-month course of antibiotics is required to treat infected patients. The pathogen Mycobacterium tuberculosis skilfully evades the weapons available to the body, as well as to medicine. "The pathogen establishes itself in macrophages and obstructs an efficient immune response," Stefan Kaufmann explains. Inside these phagocytes, which actually support the body's immune system defences, the bacteria can remain inactive and survive for long periods of time, and so escape the majority of antibiotics. The thick, impermeable fat layer in the cell wall also provides protection for the pathogen.

"The old BCG vaccine against tuberculosis primarily activates only helper cells. The trick with our new vaccine is to additionally activate the killer cells, which enables us to trigger an improved immune system response," Kaufmann continues. In addition to research into vaccines, innovative treatments are also being investigated which attempt to entice the bacteria out of their macrophage hiding places.


Story Source:

The above story is based on materials provided by Lindau Meeting of Nobel Laureates. Note: Materials may be edited for content and length.


Cite This Page:

Lindau Meeting of Nobel Laureates. "Progress in fight against tuberculosis." ScienceDaily. ScienceDaily, 30 June 2014. <www.sciencedaily.com/releases/2014/06/140630114149.htm>.
Lindau Meeting of Nobel Laureates. (2014, June 30). Progress in fight against tuberculosis. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2014/06/140630114149.htm
Lindau Meeting of Nobel Laureates. "Progress in fight against tuberculosis." ScienceDaily. www.sciencedaily.com/releases/2014/06/140630114149.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Stone Fruit Listeria Scare Causes Sweeping Recall

Stone Fruit Listeria Scare Causes Sweeping Recall

Newsy (July 22, 2014) — The Wawona Packing Company has issued a voluntary recall on the stone fruit it distributes due to a possible Listeria outbreak. Video provided by Newsy
Powered by NewsLook.com
Huge Schizophrenia Study Finds Dozens Of New Genetic Causes

Huge Schizophrenia Study Finds Dozens Of New Genetic Causes

Newsy (July 22, 2014) — The 83 new genetic markers could open dozens of new avenues for schizophrenia treatment research. Video provided by Newsy
Powered by NewsLook.com
CDC Head Concerned About a Post-Antibiotic Era

CDC Head Concerned About a Post-Antibiotic Era

AP (July 22, 2014) — Sounding alarms about the growing threat of antibiotic resistance, CDC Director Tom Frieden warned Tuesday if the global community does not confront the problem soon, the world will be living in a devastating post-antibiotic era. (July 22) Video provided by AP
Powered by NewsLook.com
Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) — Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins